Comparative Study of Tadalafil And Tamsulosin in Benign Hyperplasia of Prostate For Lower Urinary Tract Symptoms (LUTS)
Abstract
Objectives: Tadalafil has been approved by the U.S. Food and Drug Administration in 2011 to treat the signs and symptoms of Lower Urinary Tract symptoms (LUTS) due to benign hyperplasia of prostate(BHP).Tamsulosin is being used to treat LUTS due to BHP.Tadalafilacts by inhibiting phosphodiesterase-5 (PDE5) thereby improving the erectile function by increasing the amount of cyclic guanosine monophosphate in the smooth muscle of the corpus cavernosa.This study aims for the comparison of tadalfil with other established drug tamsulosin in Indian population Methods: A total of 100 patient presenting with lower urinary tract symptoms( LUTS) due to BPH were selected and randomized with card method to receive either 5mg tadalafil daily or 0.4 mg tamsulosin daily.The parameters recorded includes Q max, PVR(post void residual urine), IPSS(International prostate symptom score), IIEF(International index of erectile function-erectile function) at the start of study and at end of 12 weeks.Data was analysed using Student T Test.Results: The groups were identical for statistical analysis.LUTS was improved by both tamsulosin and tadalafil.But tamsulosin is slightly more effective than tadalafil but notstatistically significant ( p > 0.05) in relieving LUTS.Only tadalafil significantly improved erectile dysfunction (p<0.05). Conclusion: Tadalafil is effective in treating the both LUTS and erectile dysfunction.Comparative Study of Tadalafil and Tamsulosin in Benign Hyperplasia of Prostate for
How strong is the evidence?
Evidence Hub reads this as a randomized trial. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.